Company news

Compugen Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Compugen Doses First Patient in COM701/Opdivo® (nivolumab) Phase 1b Cohort Expansion Study

June 29, 2021

Compugen Presents Research Supporting PVRIG as a Novel and Differentiated Checkpoint in the DNAM-1 Axis

June 28, 2021

Compugen Announces Updated Data from Phase 1 Study of COM701, First- in-Class Anti-PVRIG, at the ASCO 2021 Annual Meeting

June 7, 2021

Compugen Management to Discuss COM701 Data Presented at ASCO at Event Hosted by Truist Securities

May 31, 2021

Compugen Reports First Quarter 2021 Results

May 12, 2021

Compugen to Participate at SITC's Targets for Cancer Immunotherapy: A Deep Dive Seminar Series

May 10, 2021

Compugen Announces Expansion of Research Collaboration with Johns Hopkins University for a Novel Myeloid Target Discovered by Compugen

May 9, 2021

Compugen to Release First Quarter 2021 Results on Thursday, May 13, 2021

May 2, 2021

Compugen to Present Data Update on COM701 Phase 1 Clinical Trial at the American Society of Clinical Oncology 2021 Annual Meeting

April 28, 2021

Compugen Publishes Preclinical Data Demonstrating Therapeutic Potential of COM902 in Cancer Immunology, Immunotherapy

April 26, 2021

Compugen Publishes Review on Biology and Potential Therapeutic Relevance of DNAM-1 axis in Cancer Immunotherapy

March 8, 2021

Compugen to Present at the Oppenheimer 31st Annual Healthcare Conference

March 7, 2021

Compugen Reports Fourth Quarter and Full Year 2020 Results

February 24, 2021

Compugen Announces Data Update from COM701 Phase 1 Clinical Trial

February 24, 2021

Compugen Expands Clinical Collaboration Agreement with Bristol Myers Squibb with Phase 1b Combination Study of COM701 with Opdivo®

February 21, 2021

Compugen to Release Fourth Quarter and Full Year 2020 Results on Thursday, February 25, 2021

February 15, 2021

Compugen Announces First Development Milestone in License Agreement with AstraZeneca for the Development of Bispecific and Multi-specific Antibody Products

December 22, 2020

Compugen Reports Third Quarter 2020 Results

November 4, 2020

Compugen Further Expands Patent Portfolio for TIGIT Inhibitor COM902 with Composition of Matter Patent in China

November 1, 2020

Compugen Presents New Research Data Further Supporting PVRIG as a Potentially Promising Target for Cancer Immunotherapy

October 26, 2020

Compugen to Release Third Quarter 2020 Results on Thursday, November 5, 2020

October 21, 2020

Compugen Announces Addition of Immuno-oncology Pioneer Dr. Nils Lonberg to its Scientific Advisory Board

September 29, 2020

Compugen Doses First Patient in Phase 1/2 Triple Combination Study of COM701 with Bristol Myers Squibb's Opdivo® and Anti-TIGIT Antibody

September 7, 2020

Compugen to Present at Upcoming September 2020 Investor Conferences

September 2, 2020

Compugen Expands Patent Portfolio for TIGIT Inhibitor COM902 with New US Composition of Matter Patent

August 27, 2020

Compugen Reports Second Quarter 2020 Results

July 29, 2020

Compugen to Release Second Quarter 2020 Results on Thursday, July 30, 2020

July 15, 2020

Compugen Announces Appointment of Dr. Oliver Froescheis as Senior Vice President, Corporate and Business Development

January 7, 2020

Compugen Added to the NASDAQ Biotechnology Index

December 19, 2019

Compugen Reports Third Quarter 2019 Results

November 10, 2019

Compugen Expands Patent Portfolio for COM902 with New Composition of Matter and Use Patent in Europe

November 5, 2019

Compugen Presents Preclinical Data for COM902 Anti-TIGIT Program at SITC 2019

November 4, 2019

Compugen Presents Initial Clinical Data from Ongoing Phase 1 Trial of COM701 in Patients with Advanced Solid Tumors at SITC 2019

November 4, 2019

Compugen Announces FDA Clearance of IND Application for COM902

November 3, 2019

Compugen to Release Third Quarter 2019 Results on Monday, November 11, 2019

October 27, 2019

Compugen to Present Data from Ongoing COM701 Phase 1 Clinical Trial at SITC 2019

October 1, 2019

Compugen Presents Update on COM701 Phase 1 Study at 2019 IGCS

September 18, 2019

Compugen Reports Second Quarter 2019 Results

August 4, 2019

Compugen Second Quarter 2019 Conference Call Scheduled for Monday, August 5, 2019 at 8: 30 AM ET

July 21, 2019

Compugen Expands Intellectual Property Portfolio for COM701 with New U.S. Patent Covering Combination Use with anti-PD-1 Antibody

July 15, 2019

Compugen Appoints Eran Perry to Its Board of Directors

July 1, 2019

Compugen to Present at the Jefferies 2019 Healthcare Conference

May 21, 2019

Compugen First Quarter 2019 Conference Call Scheduled for Monday, May 20, 2019 at 8: 30 AM ET

May 5, 2019

Compugen Presents Update on COM701 Phase 1 Trial at the 2019 AACR Annual Meeting

April 2, 2019

← Newer news releases

Calls

The 5 newest of 19 calls. Every call is listed under its year.

Decks

The 5 newest of 8 decks. Every deck is listed under its year.